Opinion statement
-
Depression is very common in Parkinson’s disease (PD), but its severity and particular symptoms vary. It can often be difficult to diagnose because many of the symptoms typically associated with depression (eg, sleep difficulties, fatigue) can be seen in nondepressed patients with PD, and signs thought to represent depression (eg, lack of facial expression, slowness) can be produced by PD itself. Apathy, although a possible feature of depression, can exist apart from depression and is often associated with cognitive impairment. Therefore, when evaluating patients with PD for possible depression, one should concentrate on the psychological or ideational aspects of the illness. One must determine whether the patient feels sad or hopeless or has a marked inability to enjoy life.
-
Once it has been determined that the patient has clinically significant depressive symptoms, it is important to let him or her know that depression is an aspect of PD requiring treatment, just like the motor manifestations of the disease. The idea of adding antidepressant medications and the possibility of psychotherapy should be introduced. A very reasonable first-choice antidepressant is either sertraline or paroxetine. Because of isolated case reports of worsening motor function associated with institution of a selective serotonin reuptake inhibitor (SSRI), one should keep track of when the medication was started so that the patient can be seen again within a month. It is important from a psychological perspective to have regular follow-up visits when treating depression. If the SSRIs are ineffective or not tolerated, nortriptyline is a good next choice. It has fewer anticholinergic effects and is less likely to cause or worsen orthostatic hypotension than other tricyclic antidepressants. Amitriptyline, although an old favorite of neurologists, is very sedating and has too much anticholinergic activity to be well tolerated in the higher doses needed to treat depression. If a patient could benefit from a dopamine agonist from a motor standpoint and his or her depressive symptoms are mild, consider using pramipexole, which may improve mood and motivation (although this has not yet been proven in a well-controlled trial).
-
It is a good idea to keep patients on antidepressant therapy at least 6 months; many patients require long-term treatment. If a patient is severely depressed, he or she should be referred to a psychiatrist, who may consider admission to the hospital and possible electroconvulsive therapy.
Similar content being viewed by others
References and Recommended Reading
Dooneief G, Mirabello E, Bell K, et al.: An estimate of the incidence of depression in idiopathic Parkinson’s disease. Arch Neurol 1992, 49:305–307.
Liu CY, Wang SJ, Fuh JL, et al.: The correlation of depression with functional activity in Parkinson’s disease. J Neurol 1997, 244:493–498.
Klaassen T, Verhey FRJ, Sneijders GH, et al.: Treatment of depression in Parkinson’s disease. A meta-analysis. J Neuropsychiatry Clin Neurosci 1995, 7:281–286.
Richard IH, Kurlan R: A survey of antidepressant usage in Parkinson’s disease. Neurology 1997, 49:1168–1170.
Schneider LS, Small GW, Hamilton SH, et al.: Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry 1997, 5:97–106.
Sternbach H: The serotonin syndrome. Am J Psychiatry 1991, 148:705–713.
Suchowersky O, deVries JD: Interaction of fluoxetine and selegiline. Can J Psychiatry 1990, 35:571–572.
Waters CH: Fluoxetine and selegiline—lack of significant interaction. Can J Neurol Sci 1994, 21:259–261.
Toyama SC, Iocono RP: Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Ann Pharmacother 1994, 28:405–406.
Laine K, Anttila M, Heinonen E, et al.: Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997, 20:419–433.
Richard IH, Kurlan R, Tanner C, et al.: Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Neurology 1997, 48:1070–1077. This article provides 1) an overview of the serotonin syndrome, 2) details regarding the reports of adverse events in patients with PD who used antidepressants in combination with selegiline, and 3) the authors’ interpretation of the literature and recommendations.
Hauser RA, Zesiewicz TA: Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord 1997, 12:756–759.
Shulman LM, Singer C, Liefert R, et al.: Therapeutic effects of sertraline (Zoloft) in patients with Parkinson’s disease (PD) [abstract]. Mov Disord 1996, 1:12.
McCance-Katz EF, Marek KL, Price LH: Serotonergic dysfunction in depression associated with Parkinson’s disease. Neurology 1992, 42:1813–1814.
Montastruc JL, Fabre N, Blin O: Does fluoxetine aggravate Parkinson’s disease? A pilot prospective study. Mov Disord 1995, 10:355–357.
Leonard BE, Faherty C: SSRIs and movement disorders. Is serotonin the culprit? Hum Psychopharmacol 1996, 11(suppl):75–82. This article provides an overview of the literature pertaining to SSRI-induced movement disorders and a discussion of possible mechanisms.
Steur ENH: Increase of Parkinson disability after fluoxetine medication. Neurology 1993, 43:211–213.
Simons JA: Fluoxetine in Parkinson’s disease. Mov Disord 1996, 11:581–582.
Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, et al.: Parkinsonism exacerbated by paroxetine. Neurology 1994, 44:2406.
Meco G, Bonifati V, Fabrizio E: Worsening of parkinsonism with fluvoxamine: two cases. Hum Psychopharmacol 1994, 9:439–441.
Brod TM: Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989, 146:1352–1353.
Caley CF, Friedman JH: Does fluoxetine exacerbate Parkinson’s disease? J Clin Psychiatry 1992, 53:278–282.
Richard IH, Maughan A, Kurlan R: Do serotonin reuptake inhibitor antidepressants worsen Parkinson’s disease? A retrospective case series. Mov Disord 1999, 14:155–157.
Jonsson B, Bebbington PE: What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994, 164:665–673.
Strong RR: Imipramine in treatment of parkinsonism: a double blind placebo study. Br Med J 1965, 2:33–34.
Laitinen L: Desipramine in treatment of Parkinson’s disease. Acta Neurol Scand 1969, 45:109–113.
Anderson J, Aabro E, Gulmann N: Anti-depressive treatment in Parkinson’s disease. A controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-dopa. Acta Neurol Scand 1980, 62:210–219.
Goetz CG, Tanner CM, Klawans HL: Bupropion in Parkinson’s disease. Neurology 1984, 34:1092–1094.
Fahn S, Chouinard S: Experience with tranylcypromine in early Parkinson’s disease. J Neural Transm 1998, 52:49–61.
Steur EN, Ballering LA: Moclobemide and selegiline in the treatment of depression in Parkinson’s disease [letter]. J Neurol Neurosurg Psychiatry 1997, 63:547.
Illi A, Sundberg S, Ojala-Karlsson P, et al.: Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects of hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996, 59:450–457.
Szegedi A, Hillert A, Wetzel H, et al.: Pramipexole, a dopamine agonist, in major depression: antidepressant effects and tolerability in an open-label study with multiple doses. Clin Neuropharmacol 1997, 20:S36-S45.
Huber TJ, Dietrich DE, Emrich HM: Possible use of amantadine in depression. Pharmacopsychiatry 1999, 32:47–55.
DasGupta K: Treatment of depression in elderly patients. Recent advances. Arch Fam Med 1998, 7:274–280. This is a very straightforward and practical article that provides an overview of treatment approaches to depression in the elderly.
Aarsland D, Larsen JP, Waage O, Langeveld JH: Maintenance electroconvulsive therapy for Parkinson’s disease. Convuls Ther 1997, 13:274–277.
Miller MD, Wolfson L, Frank E, et al.: Using interpersonal psychotherapy (IPT) in a combined psychotherapy/ medication research protocol with depressed elders. A descriptive report of case vignettes. J Psychother 1997, 7:47–55.
George MS, Wassermann EM, Post RM: Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. J Neuropsychiatry Clin Neurosci 1996, 8:373–382. This article provides an overview of the relatively new technique known as transcranial magnetic stimulation, which may have relevance to PD and depression.
Kumar R, Chen R, Ashby P: Safety of transcranial magnetic stimulation in patients with implanted deep brain stimulators. Mov Disord 1999, 14:157–185.
George MS, Wassermann EM, Kimbrell TA, et al.: Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am J Psychiatry 1997, 154:1752–1756.
Mattes JA: Mood improvement from transcranial magnetic stimulation [letter]. Am J Psychiatry 1999, 156:669.
Klein E, Kreinin I, Chistyakov A, et al.: Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a doubleblind controlled study. Arch Gen Psychiatry 1999, 56:315–320.
Mally J, Stone TW: Improvement in parkinsonian symptoms after repetitive transcranial magnetic stimulation. J Neurol Sci 1999, 162:179–184.
Siebner HR, Mentschel C, Auer C, Conrad B: Repetitive transcranial magnetic stimulation has a beneficial effect on bradykinesia in Parkinson’s disease. Neuroreport 1999, 10:589–594.
Ghabra MB, Hallett M, Wassermann EM: Simultaneous repetitive transcranial magnetic stimulation does not speed fine movement in PD. Neurology 1999, 52:768–770.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Richard, I.H. Depression in Parkinson’s disease. Curr Treat Options Neurol 2, 263–273 (2000). https://doi.org/10.1007/s11940-000-0008-z
Issue Date:
DOI: https://doi.org/10.1007/s11940-000-0008-z